StockData
PharmaCyte Biotech, Inc. logo

PharmaCyte Biotech, Inc. (PMCB) stock

PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 6/30
$5.42−0.15 (-2.69%)

Close on Nov 17, 2026Market cap $58.19MP/E –Yield –

PharmaCyte Biotech pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

PharmaCyte Biotech's pe ratio was 0.3× on May 29, 2026, against 1.3× a year earlier. Over the last 2 years it ranged from 0.2× to 47.2×, with a median of 1.3×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026May 29, 20260.3×+0.1
2025Dec 31, 20250.2×−2.6
2024Dec 31, 20242.8×–

More PharmaCyte Biotech figures

See a number that looks wrong?